Financial Performance - The company reported a net loss of $18.1 million for Q2 2022, compared to a net loss of $11.0 million for Q2 2021, indicating a year-over-year increase in losses [64]. - Net loss for the three months ended June 30, 2022, was $18.1 million, an increase of $7.1 million (64.4%) from a net loss of $11.0 million in the same period of 2021 [84]. - Total operating expenses for the six months ended June 30, 2022, were $42.9 million, an increase of $11.3 million (35.7%) from $31.6 million in the same period of 2021 [91]. - The company has incurred operating losses since inception and expects to continue significant expenses and losses for the foreseeable future [106]. Cash and Investments - Total cash, cash equivalents, restricted cash, and investments as of June 30, 2022, amounted to $201.2 million [64]. - Cash, cash equivalents, restricted cash, and investments totaled $201.2 million as of June 30, 2022 [97]. - Net cash used in operating activities for the six months ended June 30, 2022, was $10.6 million, a decrease from $30.7 million in the same period of 2021 [102]. - Net cash used in investing activities was $31.2 million for the six months ended June 30, 2022, primarily for net purchases of investments [103]. - The company had $5.8 million in remaining principal balance under its 2019 term loan agreement as of June 30, 2022 [100]. Research and Development - Acazicolcept (ALPN-101) is currently in a Phase 2 study for moderate-to-severe systemic lupus erythematosus (SLE), with $105.0 million received in upfront and milestone payments from AbbVie [59]. - ALPN-303 is in a Phase 1 study, with initial clinical data from basket trials expected in the second half of 2023 [59]. - Davoceticept (ALPN-202) has shown tumor volume reduction in 23% of evaluable participants in a Phase 1 study, with preliminary data from expansion cohorts anticipated in the second half of 2023 [62]. - The company expects research and development expenses to increase in the foreseeable future as it continues to develop its platform and product candidates [75]. - Total direct research and development expenses for Q2 2022 were $9.0 million, an increase from $8.3 million in Q2 2021 [75]. - Total research and development expenses for the first half of 2022 were $33.9 million, compared to $25.1 million for the same period in 2021 [75]. - Indirect research and development expenses increased to $8.5 million in Q2 2022 from $6.3 million in Q2 2021 [75]. - Research and development expenses increased by $3.0 million (20.2%) to $17.6 million for the three months ended June 30, 2022, primarily due to clinical trial activities and personnel-related expenses [86]. Collaboration Agreements - The company has raised an aggregate of $418.1 million since inception, with $185.6 million from common stock sales and $139.2 million from collaboration agreements [64]. - An exclusive collaboration agreement with Horizon Therapeutics includes an upfront payment of $25.0 million and potential future payments of up to $1.5 billion [59]. - AbbVie Agreement includes a nonrefundable upfront payment of $60.0 million and potential cash payments up to $75.0 million upon achieving predefined development milestones [66]. - Revenue recognized from the AbbVie Agreement was $4.6 million for Q2 2022, compared to $7.2 million for Q2 2021, and $10.5 million for the first half of 2022, compared to $10.4 million for the same period in 2021 [68]. - Horizon Agreement resulted in an upfront payment of $25.0 million and an equity investment of $15.0 million, with potential future success-based payments of up to $1.5 billion [69]. - Revenue recognized from the Horizon Agreement was $0.6 million for Q2 2022 and $8.3 million for the first half of 2022 [69]. - Collaboration revenue for the three months ended June 30, 2022, was $5.3 million, a decrease of $1.9 million (35.5%) compared to $7.2 million in the same period of 2021 [84]. - For the six months ended June 30, 2022, collaboration revenue was $18.9 million, an increase of $8.5 million (81.8%) compared to $10.4 million in the same period of 2021 [91]. Future Outlook - The company expects to incur significant expenses and operating losses for several years as it continues clinical trials and research and development efforts [64]. - Future revenue is expected to fluctuate based on collaboration and licensing agreements, with potential milestone payments from partners like AbbVie and Horizon [65]. - Future capital requirements are difficult to forecast and will depend on various factors, including the number of product candidates pursued and the costs of clinical trials [106]. - The company anticipates needing to finance cash needs through equity or debt financings and collaboration agreements, which may dilute existing stockholders' ownership [106]. Lease and Tax Provisions - The annual base rent for the office and laboratory space is $1.7 million for the first year, increasing by 3.0% each year thereafter [107]. - A tenant improvement allowance of $5.4 million is included in the base rent, with an additional maximum allowance of $1.8 million amortized over the lease term [107]. - An estimated current foreign income tax provision of $1.3 million has been recorded for expected repayments related to research and development expenditures [108]. - The increase in income tax expense for the six months ended June 30, 2022, was $1.7 million, primarily due to a cumulative change in foreign income tax provision [96]. - The company is not required to provide quantitative and qualitative disclosures about market risk as a "smaller reporting company" [109].

Financial Performance - The company reported a net loss of $7.5 million for the three months ended March 31, 2022, compared to a net loss of $10.6 million for the same period in 2021, indicating a reduction in losses year-over-year [62]. - The company reported a net loss of $7.5 million for the three months ended March 31, 2022, an improvement from a net loss of $10.6 million in the same period in 2021, reflecting a decrease of 29% [78]. - Collaboration revenue for the three months ended March 31, 2022, was $13.6 million, a significant increase from $3.2 million in the same period in 2021, representing a growth of approximately 326% [78]. - Revenue recognized from the AbbVie Agreement was $6 million for Q1 2022, compared to $3.2 million for Q1 2021 [66]. - Revenue recognized from the Horizon Agreement was $7.7 million for Q1 2022 [67]. - The company has not generated any product sales to date and does not expect to generate product revenue until successful development and commercialization of its product candidates [63]. Cash and Investments - As of March 31, 2022, the company had cash, cash equivalents, restricted cash, and investments totaling $219.1 million, which is crucial for funding ongoing operations and clinical trials [62]. - As of March 31, 2022, the company had cash and investments totaling $219.1 million, providing a solid liquidity position for ongoing operations [82]. - Net cash provided by operating activities was $5.4 million for the three months ended March 31, 2022, compared to a net cash used of $16.0 million in the same period in 2021 [87]. - The company received a $25.0 million upfront payment from Horizon as part of its collaboration agreement, contributing to the positive cash flow from operating activities [87]. - The company has outstanding principal of $7.0 million under its term loan agreement as of March 31, 2022, with obligations to meet certain covenants [84]. Research and Development - The company is aggressively advancing its lead autoimmune/inflammatory program, acazicolcept, through clinical development, including a Phase 2 study for systemic lupus erythematosus (SLE) [61]. - The company initiated a Phase 1 study of ALPN-303 in healthy volunteers in Q4 2021, with plans to move into clinical studies for B cell-mediated autoimmune/inflammatory diseases [61]. - The company is focused on developing davoceticept, a conditional CD28 costimulator, which has shown early evidence of clinical benefit in advanced malignancies [62]. - Research and development expenses totaled $16.3 million for Q1 2022, up from $10.4 million in Q1 2021, reflecting increased investment in product development [70]. - Direct research and development expenses by program totaled $9.1 million for Q1 2022, compared to $5.5 million for Q1 2021 [70]. - Research and development expenses increased by $5.9 million to $16.3 million, primarily due to a $3.8 million rise in clinical trial activities and $2.5 million in personnel-related expenses [80]. - The company expects to incur significant expenses and operating losses for at least the next several years as it continues to develop its product candidates and expand its pipeline [63]. - The company expects to continue incurring significant expenses and operating losses as it advances its research and clinical development efforts [91]. Collaborations and Partnerships - The company has entered into an exclusive license and collaboration agreement with Horizon Therapeutics, receiving an upfront payment of $25.0 million and an equity investment of $15.0 million, with potential future payments of up to $1.5 billion [60]. - AbbVie paid a nonrefundable upfront payment of $60 million and may pay up to $75 million upon achieving predefined development milestones [65]. - The company recognized no revenue from the Adaptimmune Agreement for Q1 2022, with potential future payments of up to $288 million based on milestone achievements [68]. - Collaboration revenue is expected to fluctuate quarterly, primarily derived from licensing agreements with AbbVie, Horizon, and Adaptimmune [64]. - Horizon made an upfront payment of $25 million and an equity investment of $15 million, with potential future payments of up to $1.5 billion based on success milestones [67]. Operational Expenses - General and administrative expenses are expected to increase as the company expands infrastructure and headcount [71]. - General and administrative expenses rose by $1.5 million to $4.8 million, driven by increases in personnel-related expenses and legal services [81]. - Interest expense primarily relates to a term loan with Silicon Valley Bank [72]. Future Outlook - The company anticipates continuing net losses and the need for potential equity or debt financing [94]. - Future capital requirements are uncertain and will depend on various factors, including the number of product candidates pursued and the costs of research and development [94]. - Available cash and cash equivalents are expected to fund operations for at least the next 12 months, based on current operating plans [94]. - The company may incur losses of up to approximately $1.8 million related to research and development credits subject to review by foreign taxing authorities [93]. - The company is exploring potential value-creating partnering opportunities to maximize the value of its pipeline and platform [62]. Lease and Facilities - The company entered into a lease for 27,164 square feet of office and laboratory space with an annual base rent of $1.7 million, increasing by 3.0% each year [92]. - A tenant improvement allowance of $5.4 million was received, with an additional maximum allowance of $1.8 million amortized over the lease term at an annual rate of 8.0% [92].

Drug Development and Regulatory Challenges - The company is developing novel protein-based immunotherapies for cancer and autoimmune/inflammatory diseases using a proprietary directed evolution platform [183]. - Limited data suggests the introduction of necessary therapeutic properties into variant Ig domain (vIgD) and variant TNF receptor domain (vTD) candidates is still being assessed [184]. - The FDA's lack of experience with vIgDs and vTDs may complicate and prolong the regulatory approval process for therapeutic candidates [185]. - The company has no products on the market, and all therapeutic candidates are in early stages of development, with significant uncertainty regarding their commercial viability [192]. - Delays in clinical trials can arise from various factors, including regulatory approval issues, patient enrollment challenges, and financial constraints [194]. - The historical failure rate for therapeutic candidates is high, and the novelty of the company's platform may lead to even higher failure rates [193]. - The company must prioritize research programs due to limited financial and operational resources, which may result in missed opportunities [196]. - Product development is lengthy and expensive, with uncertain outcomes, and earlier trial results may not predict future success [197]. - The company may face challenges in obtaining orphan drug designation and exclusivity, which could impact market potential for rare disease indications [188]. - The anticipated research and development spending will materially increase due to the Phase 2 study in systemic lupus erythematosus (SLE), which is a challenging indication with a history of failed trials by other companies [198]. - The FDA has placed a partial clinical hold on the NEON-2 trial evaluating davoceticept in combination with Merck's pembrolizumab due to a participant's death, which could delay enrollment and increase costs [213]. - The company faces competition from entities developing therapeutic candidates for similar disease indications, which may adversely affect its ability to commercialize its products [215]. - The company may encounter difficulties in patient enrollment for clinical trials due to various disruptions, including public health crises and geopolitical events [202]. - Regulatory disruptions, such as those experienced during the COVID-19 pandemic, may slow the review process for new drugs, adversely affecting the company's business [199]. - The company must navigate the risks associated with combination therapies, which may increase the rate of serious adverse events and lead to regulatory restrictions [209]. - The company competes in a highly competitive biotechnology sector, facing challenges from larger firms with greater financial resources and expertise in research and development [217]. Financial and Operational Risks - The company received an upfront payment of $60.0 million from the AbbVie Agreement and is eligible for up to $75.0 million in development milestones, with $45.0 million achieved in Q2 2021 [224]. - Under the Horizon Agreement, the company received an upfront payment of $25.0 million and an equity investment of $15.0 million, with potential milestone payments up to $381.0 million per program, totaling approximately $1.5 billion if all milestones are met [225]. - The company’s revenue is primarily derived from collaboration agreements, making its success dependent on the efforts of collaborators to develop therapeutic candidates [223]. - The company has established in-house recombinant protein generation capabilities for producing sufficient protein materials for some preclinical studies, but relies on third-party manufacturers for clinical trial supplies [233]. - The company faces risks related to the inability to present data in scientific journals or conferences, which could adversely impact its business and stock price [221]. - The company’s scientific platform and mechanisms of action are not conclusively proven, which may hinder its ability to raise capital and obtain regulatory approvals [220]. - The company’s collaborations may result in reduced royalty revenues if patent protection is not maintained, affecting anticipated revenue from collaborators [226]. - The company’s development programs could be delayed if third parties responsible for clinical trials do not perform as expected, impacting financial results and operations [228]. - The company’s reliance on third-party manufacturing and supply partners may lead to limitations or interruptions in the supply of clinical trial materials [232]. - The company must ensure compliance with FDA and regulatory authority requirements for manufacturing, and any failure could result in delays and negatively affect business prospects [234]. - The company expects to continue relying on third-party manufacturers for therapeutic candidates if regulatory approval is received, which poses risks related to timely performance and quality control [237]. - Changes in manufacturing methods and processes during product development may lead to delays in clinical trials and increased costs, potentially jeopardizing commercialization [238]. - The company may face challenges in engaging in strategic transactions, which could adversely affect its ability to develop and commercialize therapeutic candidates and impact cash position [239]. - The company currently lacks sales, marketing, or distribution capabilities, which may hinder successful commercialization of approved therapeutic candidates [245]. - As of December 31, 2021, the company had $215.4 million in cash and cash equivalents, which is expected to fund operations for at least the next 12 months [259]. - The company will need to raise substantial additional funds to advance development and commercialization of therapeutic candidates, with future capital requirements being highly uncertain [258]. - Regulatory compliance is critical, as failure to meet requirements could result in penalties, delays, or withdrawal of marketing approvals [246]. - The company may face economic, political, and regulatory risks associated with international operations, which could impact future results [255]. - Pricing negotiations for prescription drugs are subject to governmental control, which may adversely affect future profitability [253]. - The company issued 4,706,700 shares of common stock and warrants in January 2019 for gross proceeds of approximately $25.3 million, followed by 5,139,610 shares in July 2020 for approximately $60.0 million, and 6,489,357 shares in September 2021 for approximately $91.0 million [263]. - For the year ended December 31, 2021, the company reported a net loss of $50.3 million, primarily due to research program expenses and general administrative costs [266]. - The company has not generated any revenue from product sales and does not expect to do so for the foreseeable future, anticipating continued significant operating losses [267]. - The company has a sales agreement with Cowen to sell up to $75.0 million of common stock through an "at the market" equity offering [263]. - The company faces risks related to product liability, which could delay development programs and result in significant financial repercussions [275]. - The company is subject to extensive regulations in the healthcare industry, which may restrict various business arrangements and increase compliance costs [277]. - The company has limited experience in therapeutic development and clinical trials, which may hinder its ability to manage growth and operations effectively [273]. - Employee misconduct poses a risk that could lead to regulatory sanctions and harm the company's reputation and financial condition [276]. - The company has incurred significant operating costs due to inflationary pressures, which may continue to impact financial results [266]. - The company must comply with environmental laws regarding hazardous materials, which could lead to substantial liabilities and operational disruptions [282]. - As of December 31, 2021, the company had $215.4 million in cash and cash equivalents, restricted cash, and investments [288]. - The company may face significant costs and operational disruptions due to potential litigation and government investigations, which could adversely affect its financial condition [286][287]. - The company’s ability to utilize pre-merger net operating loss carryforwards may be limited due to ownership changes resulting from the merger [290][291]. - The company’s term loan agreement imposes various covenants that could restrict its ability to pursue business strategies, including mergers and acquisitions [292][294]. Intellectual Property and Legal Risks - The company has a patent portfolio consisting of 47 granted patents and over 155 pending patent applications as of December 31, 2021 [310]. - The company may face significant costs and management distraction due to potential litigation over patent infringement claims [321]. - Patent protection has a limited lifespan, generally expiring 20 years from the earliest non-provisional filing date, which may expose the company to competition shortly after product commercialization [317]. - The company has in-licensed some intellectual property on a non-exclusive basis, which may limit its competitive position if not adequately protected [316]. - The company may not be able to effectively protect its intellectual property rights in jurisdictions outside the United States, leading to increased competition [319]. - The company is subject to risks related to the enforcement of its patents, which may be challenged or invalidated, impacting its market position [322]. - The company has not undertaken a systematic analysis of potential disaster impacts on its operations, which could materially affect its financial results [307]. - The company relies on third-party licensors for some intellectual property rights, and any failure on their part could adversely affect the company's business prospects [315]. - The company faces uncertainties in obtaining and maintaining patent protection due to procedural and legal complexities in various jurisdictions [312]. - The company may need to pursue litigation to protect its intellectual property rights, which could be costly and time-consuming [324]. - The company faces potential legal challenges regarding patent validity, which could result in losing patent protection for its technology and products, significantly impacting its business [325]. - There is a risk of failing to identify relevant third-party patents, which could lead to costly litigation and delays in marketing the company's technology [326]. - Non-compliance with licensing agreements may result in damages and loss of essential intellectual property rights, adversely affecting business prospects [327]. - The company may not obtain patent term extensions, which could harm its business if competitors launch products after patent expiration [329]. Market and Pricing Risks - Regulatory approval for therapeutic candidates is uncertain and may take many years, with no current approvals obtained [339][340]. - The company has limited experience in managing clinical trials, which could lead to unpredictable delays in obtaining regulatory approvals [340]. - The FDA or foreign regulatory authorities may disagree with clinical trial designs or results, potentially preventing approval of therapeutic candidates [343]. - The company may face claims regarding the improper use of trade secrets from former employers of its employees, leading to costly litigation and potential loss of intellectual property [333]. - Breaches of internal computer systems could compromise proprietary information, affecting the company's financial condition and business prospects [336]. - The company must comply with various regulatory requirements, which are costly and time-consuming, and may face unexpected delays due to changes in regulations [341]. - The company is subject to substantial discretion from regulatory authorities like the FDA and EMA, which may delay or prevent revenue generation from therapeutic candidates [344]. - The company may seek orphan drug designation from the FDA and EMA, which could provide financial incentives and exclusivity for products intended to treat rare diseases [347][348]. - Orphan drug designation in the U.S. grants seven years of exclusivity post-approval, while in the EU, it can provide up to ten years unless certain conditions are met [348]. - The company faces risks associated with compliance to healthcare laws, which could lead to enforcement actions affecting its ability to market and sell therapeutics [352][356]. - Future legislation may increase the difficulty and cost of obtaining marketing approval for therapeutic candidates [357]. - The company may experience significant delays in obtaining coverage and reimbursement for newly-approved therapeutics, impacting financial results [362]. - Pricing regulations in various countries may delay commercial launches and negatively affect revenue generation from approved products [361]. - Third-party payors often rely on Medicare coverage policies, which may affect reimbursement rates for the company's therapeutics [363]. - The company must navigate complex healthcare regulations, which could involve substantial costs and affect operational compliance [354][355]. - Regulatory approval processes vary by country, and approval by the FDA does not guarantee approval by other regulatory authorities [346]. - Legislative and regulatory changes in the U.S. healthcare system may adversely affect the pricing and reimbursement of therapeutics, impacting the company's ability to sell products at favorable prices [364]. - The annual 2% reduction to Medicare payments, effective since 2013 and lasting through 2031, could lead to a reduction in future revenues, earnings, and cash flows for the company [366]. - The elimination of the statutory cap on Medicaid Drug Rebate Program rebates, effective January 1, 2024, may require the company to pay more in rebates than it receives from product sales, significantly impacting its business [369]. - Increased scrutiny on specialty drug pricing practices and proposed legislation aimed at enhancing transparency and reducing drug costs could impose additional compliance burdens on the company [367]. Data Protection and Compliance Risks - The implementation of the GDPR and other data protection regulations may increase operational costs and compliance complexities for the company, potentially leading to significant fines for violations [373]. - The California Consumer Privacy Act (CCPA) and its subsequent amendments may increase compliance costs and potential liabilities for the company regarding personal data handling [378]. - The company may face increased liabilities and operational losses due to compliance with GDPR and local laws in the EU, UK, and other regions [377]. - Future healthcare reforms could limit federal and state government payments for healthcare products, resulting in reduced demand for the company's product candidates [370]. - The company's operations and clinical trials will be subject to extensive regulation, and any violations could lead to significant penalties and negatively affect its financial condition [371]. - The uncertainty surrounding data protection regulations post-Brexit may require the company to adapt to dual regulatory regimes, increasing compliance costs and operational complexities [375]. - The U.S. federal budget is uncertain, with potential cuts to Medicare payments to providers, which may impact the company's services and funding [380]. - Future reductions in federal spending could lead to budgetary shortfalls affecting agencies like the FDA and NIH, potentially delaying drug research and development [380]. - The company cannot predict the full impact of legislative actions from the Biden administration on its operations and the biopharmaceutical industry [380].

Strategic Partnership - Alpine entered a strategic partnership with Horizon Therapeutics, receiving a \$25 million upfront payment and a \$15 million equity investment at a 25% premium, with potential milestones totaling \$1.52 billion[6,8] - Alpine also has a strategic partnership with AbbVie for Acazicolcept, including a \$60 million upfront payment and up to \$805 million in potential option exercise and milestone payments[87] Davoceticept (ALPN-202) - Davoceticept is being evaluated in a Phase 1/1b study as monotherapy and in combination with KEYTRUDA® for advanced malignancies[5] - In preclinical studies, Davoceticept demonstrated superior efficacy to PD-L1 inhibition as a monotherapy[25,27] - In a Phase 1 study with 32 subjects, 66% experienced any related adverse event, and 3% experienced a Grade ≥ 3 related adverse event[32,33] - Early clinical data for Davoceticept monotherapy showed a partial response in 4.3% and stable disease in 57% of evaluable patients[38] ALPN-303 - ALPN-303 is a dual B cell cytokine antagonist targeting BAFF and APRIL, with a Phase 1 study in healthy volunteers anticipated in mid-2022[5] - Preclinical data suggests ALPN-303 exhibits superior BAFF/APRIL inhibition compared to existing inhibitors[55] - In non-human primates, ALPN-303 demonstrated increased exposure and enhanced immunoglobulin suppression compared to WT TACI-Fc[62] Acazicolcept (ALPN-101) - Acazicolcept is a dual CD28/ICOS antagonist being developed for autoimmune/inflammatory diseases and is currently in Phase 2 for Systemic Lupus Erythematosus[5,85] - Phase 1 data showed dose-proportional PK/PD and was well-tolerated in humans[83,84]

Financial Overview - As of September 30, 2021, the company has raised an aggregate of $378.2 million to fund operations, with $170.7 million from common stock sales, $49.2 million from convertible preferred stock, and $114.2 million from collaboration agreements[57]. - The net loss for the three months ended September 30, 2021, was $13.5 million, compared to $6.1 million for the same period in 2020[57]. - The company had cash, cash equivalents, restricted cash, and investments totaling $219.9 million as of September 30, 2021[57]. - The net loss for the nine months ended September 30, 2021, was $35.2 million, compared to a net loss of $21.6 million in the same period of 2020, indicating an increase in losses of 63%[83]. - The company reported a net cash used in operating activities of $0.5 million for the nine months ended September 30, 2021, compared to a net cash provided of $39.4 million for the same period in 2020[100]. - The net cash used in investing activities was $48.2 million for the nine months ended September 30, 2021, primarily due to purchases and maturities of investments and property and equipment[101]. - The net cash provided by financing activities was $89.9 million for the nine months ended September 30, 2021, mainly from the sale of approximately 6.5 million shares of common stock[102]. Collaboration Agreements - The company has received $105.0 million in upfront and pre-option exercise development milestones from the collaboration agreement with AbbVie[56]. - AbbVie Agreement resulted in a nonrefundable upfront payment of $60.0 million and potential milestone payments totaling up to $450.0 million upon achievement of sales-based milestones[60]. - Revenue recognized from the AbbVie Agreement was $8.5 million for Q3 2021, compared to $1.6 million for Q3 2020, reflecting an increase of $6.6 million[76]. - Collaboration revenue for the nine months ended September 30, 2021, was $18.9 million, a significant increase from $3.7 million in the same period of 2020, representing a growth of 410%[84]. - The collaboration and licensing agreements are expected to generate fluctuating revenue in the future, primarily from milestone payments[59]. Research and Development - The lead oncology program, ALPN-202, demonstrated clinical benefit in 61% of evaluable patients in a Phase 1 study, despite most having tumors considered non-responsive to immunotherapies[56]. - The company plans to initiate patient-based studies for ALPN-303 in the second half of 2022, targeting various autoimmune and inflammatory diseases[56]. - The first-in-human Phase 1 study of ALPN-303 is expected to begin in Q4 2021, with topline results targeted for the first half of 2022[56]. - Research and development expenses increased to $18.3 million in Q3 2021 from $6.2 million in Q3 2020, a rise of $12.2 million[62]. - Research and development expenses for the nine months ended September 30, 2021, totaled $43.4 million, compared to $18.1 million for the same period in 2020[62]. - Research and development expenses increased by $25.3 million, primarily due to clinical trial activities and contract manufacturing, with specific increases of $8.3 million and $7.9 million respectively[85]. Operating Expenses - Total operating expenses for Q3 2021 were $21.8 million, up from $8.9 million in Q3 2020, marking an increase of $12.9 million[76]. - Total operating expenses for the nine months ended September 30, 2021, were $53.4 million, up from $26.0 million in 2020, reflecting an increase of 105%[83]. - General and administrative expenses rose to $3.5 million in Q3 2021 from $2.7 million in Q3 2020, an increase of $0.7 million[79]. - General and administrative expenses rose by $2.2 million, mainly driven by personnel-related expenses and non-cash stock-based compensation[86]. Future Expectations - The company expects to incur significant expenses and operating losses for at least the next several years as it continues clinical trials and research efforts[57]. - The company expects to continue incurring significant expenses and operating losses as it advances its research and development efforts[89]. - The company has incurred operating losses since inception and anticipates the need for potential equity or debt financing in the future[89]. Lease and Other Financial Obligations - The company has a lease for 27,164 square feet of office and laboratory space with an annual base rent of $1.7 million, increasing by 3.0% each year[96]. - The company received a tenant improvement allowance of $5.4 million, with an additional maximum allowance of $1.8 million amortized over the lease term at an annual rate of 8.0%[96]. - The company may incur losses of up to approximately $1.8 million related to credits received for research and development expenditures, subject to review by foreign tax authorities[97]. - The company did not have any off-balance sheet arrangements during the periods presented[104]. - As a smaller reporting company, the company is not required to provide additional information on contractual obligations and contingent liabilities[103].

Financial Performance - The company reported a net loss of $10.6 million for the three months ended March 31, 2021, compared to a net loss of $5.5 million for the same period in 2020[62]. - The net loss for the three months ended March 31, 2021, was $10.6 million, compared to a net loss of $5.5 million for the same period in 2020, indicating an increase in losses of 92%[78]. - Collaboration revenue for the three months ended March 31, 2021, was $3.2 million, up from $1.1 million in the same period in 2020, reflecting a 194% increase[80]. - Research and development expenses increased to $10.4 million for the three months ended March 31, 2021, compared to $4.9 million for the same period in 2020, representing a 112% increase[69]. - Total operating expenses rose to $13.7 million for the three months ended March 31, 2021, compared to $6.7 million for the same period in 2020, marking a 106% increase[78]. Cash and Investments - As of March 31, 2021, the company had cash, cash equivalents, restricted cash, and investments totaling $115.4 million[62]. - The company raised an aggregate of $242.4 million to fund operations, including $79.9 million from the sale of common stock and $69.2 million from license and collaboration agreements[86]. - Net cash used in operating activities was $16.0 million for the three months ended March 31, 2021, compared to $9.7 million for the same period in 2020[94]. - Net cash used in investing activities was $6.5 million for the three months ended March 31, 2021, compared to a net cash provided of $13.1 million for the same period in 2020[96]. - Net cash provided by financing activities was $0.2 million for the three months ended March 31, 2021, compared to $5.0 million for the same period in 2020[97]. Agreements and Collaborations - The company recognized revenue of $3.2 million from the AbbVie Agreement for the three months ended March 31, 2021, with a remaining balance of $49.8 million recorded as deferred revenue[65]. - The AbbVie Agreement includes a nonrefundable upfront payment of $60 million and potential milestone payments totaling up to $205 million, plus royalties on worldwide net sales[64]. - The Adaptimmune Agreement has the potential for additional research support payments and milestones totaling up to $288 million[66]. - The company aims to maximize the value of its pipeline through potential partnering activities and collaborations[61]. Research and Development - The company plans to initiate a Phase 2 study for ALPN-101 in systemic lupus erythematosus (SLE) and a Phase 1 study for ALPN-303 in B cell-mediated autoimmune diseases[61]. - The lead oncology program, ALPN-202, has shown superior efficacy in preclinical models compared to approved therapies and is currently in a Phase 1 study[61]. - The company expects to incur significant expenses and operating losses for several years as it continues clinical trials and research and development efforts[62]. - The company expects to continue incurring significant expenses and operating losses as it develops product candidates and seeks regulatory approvals[86]. Expenses and Liabilities - General and administrative expenses increased to $3.3 million for the three months ended March 31, 2021, from $1.8 million in the same period in 2020, a 83% increase[82]. - Interest expense increased by $0.1 million due to additional interest related to the drawdown of the second tranche of the term loan with Silicon Valley Bank[83]. - Interest income decreased by $0.1 million primarily due to less interest earned on investments[84]. - The company borrowed $5.0 million under the Original Agreement with SVB, which had an interest-only period until July 2018[89]. - An Amended and Restated Loan Agreement was entered into in August 2019, allowing for term loans up to $15.0 million, with the first tranche of $5.0 million funded in August 2019[89]. - As of March 31, 2021, the company had $10.6 million in outstanding principal and final fees due under the term loan agreement[90]. - There is a potential loss of up to approximately $1.8 million related to research and development credits subject to review by foreign tax authorities[92]. - The company is in compliance with its loan covenants as of March 31, 2021[90]. Lease Obligations - The annual base rent for the office and laboratory lease is $1.7 million for the first year, increasing by 3.0% each subsequent year[91]. - The company received a tenant improvement allowance of $5.4 million, which is included in the base rent[91].

Financial Performance - The company reported a net loss of $6.1 million for Q3 2020, compared to a net loss of $11.5 million for Q3 2019, and a total net loss of $21.6 million for the nine months ended September 30, 2020, down from $35.7 million for the same period in 2019[52]. - Net loss for Q3 2020 was $6.1 million, improved from a net loss of $11.5 million in Q3 2019, representing a reduction of 46.5%[67]. - The company has incurred operating losses since inception and anticipates continuing net losses in the long term[81]. Cash and Investments - As of September 30, 2020, the company had cash, cash equivalents, restricted cash, and short-term investments totaling $141.3 million[51]. - Net cash provided by operating activities was $39.4 million for the nine months ended September 30, 2020, primarily due to a $60.0 million upfront payment from AbbVie[86]. - Net cash provided by investing activities was $24.0 million during the nine months ended September 30, 2020, reflecting net purchases and maturities of short-term investments[87]. - Net cash provided by financing activities was $61.4 million for the nine months ended September 30, 2020, mainly from the sale of approximately 5.9 million units under the July 2020 Securities Purchase Agreement[88]. Revenue and Collaboration Agreements - The company entered into an agreement with AbbVie in June 2020, receiving a nonrefundable upfront payment of $60.0 million and potential milestone payments totaling up to $450.0 million[54]. - Revenue recognized from the AbbVie Agreement was $1.6 million for the three and nine months ended September 30, 2020, with a remaining deferred revenue balance of $58.4 million[55]. - Under the Adaptimmune Collaboration Agreement, the company recognized revenue of $356,000 for Q3 2020 and $2.0 million for the nine months ended September 30, 2020[55]. - Collaboration revenue for Q3 2020 was $1.9 million, an increase of $1.6 million compared to $0.3 million in Q3 2019[68]. - Collaboration revenue for the nine months ended September 30, 2020, was $3.7 million, an increase of $2.8 million compared to $0.9 million in the same period of 2019[77]. Research and Development - The company plans to initiate a Phase 2 study for ALPN-101 in adults with lupus in the first half of 2021[51]. - The lead oncology program, ALPN-202, is currently in a Phase 1 study, with updates expected in the first half of 2021[51]. - The company is conducting additional nonclinical studies for ALPN-303, aiming to enable clinical trials by the end of 2021[51]. - Research and development expenses for Q3 2020 were $6.2 million, down from $9.5 million in Q3 2019, a decrease of 34.5%[57]. - Research and development expenses for the nine months ended September 30, 2020, were $18.1 million, down from $30.0 million in the same period of 2019, a decrease of 39.6%[74]. Operating Expenses - Total operating expenses for Q3 2020 were $8.9 million, compared to $12.0 million in Q3 2019, reflecting a decrease of 26%[67]. - Total operating expenses for the nine months ended September 30, 2020, were $26.0 million, compared to $37.4 million in the same period of 2019, a decrease of 30.6%[77]. - General and administrative expenses for Q3 2020 were $2.7 million, an increase of 10.6% from $2.5 million in Q3 2019[67]. Future Outlook - The company expects to incur significant expenses and operating losses for several years as it continues clinical trials and research and development efforts[52]. - The company expects to continue incurring significant expenses and operating losses as it advances its research and development programs[80]. - The company intends to finance its cash needs through a combination of equity or debt financings and collaboration agreements[80]. - The company has no committed external sources of capital beyond milestone payments from collaborators, which may affect its ability to fund operations[81].

Financial Performance - The net loss for the three months ended June 30, 2020, was $9.9 million, compared to $11.9 million for the same period in 2019, indicating a reduction in losses[56] - Net loss for the three months ended June 30, 2020, was $9.928 million, a decrease of $1.928 million compared to a net loss of $11.856 million in the same period of 2019[72] - Net loss for the six months ended June 30, 2020, was $15.461 million, a decrease of $8.776 million compared to a net loss of $24.237 million in the same period of 2019[77] - The company expects to incur significant expenses and operating losses for at least the next several years as it continues clinical trials and research and development efforts[56] - The company expects to continue incurring significant operating losses as it advances research and clinical development of product candidates[82] - The company has incurred operating losses since inception and anticipates the need for potential equity or debt financing in the future[83] Revenue and Expenses - Collaboration revenue for the three months ended June 30, 2020, was $0.688 million, an increase of $0.121 million compared to $0.567 million in the same period of 2019[72] - Collaboration revenue for the six months ended June 30, 2020, was $1.779 million, an increase of $1.212 million compared to $0.567 million in the same period of 2019[77] - Research and development expenses for the three months ended June 30, 2020, were $7.096 million, a decrease of $3.070 million from $10.166 million in the same period of 2019[72] - Research and development expenses for the six months ended June 30, 2020, were $11.974 million, a decrease of $8.542 million from $20.516 million in the same period of 2019[77] - General and administrative expenses for the three months ended June 30, 2020, were $3.344 million, an increase of $0.791 million compared to $2.553 million in the same period of 2019[72] - General and administrative expenses for the six months ended June 30, 2020, were $5.122 million, an increase of $0.224 million compared to $4.898 million in the same period of 2019[77] - Total operating expenses for the three months ended June 30, 2020, were $10.440 million, a decrease of $2.279 million from $12.719 million in the same period of 2019[72] - Total operating expenses for the six months ended June 30, 2020, were $17.096 million, a decrease of $8.318 million from $25.414 million in the same period of 2019[77] Cash and Funding - The company raised an aggregate of $185.7 million to fund operations since inception, with $60.0 million received from a securities purchase agreement in July 2020[56] - As of June 30, 2020, the company had cash, cash equivalents, restricted cash, and short-term investments totaling $90.5 million[56] - Net cash provided by operating activities was $44.8 million for the six months ended June 30, 2020, largely due to a $60.0 million upfront payment from AbbVie[88] - Net cash provided by investing activities was $22.2 million during the same period, reflecting net purchases and maturities of short-term investments[91] - Net cash provided by financing activities was $5.0 million for the six months ended June 30, 2020, primarily from the drawdown of the second tranche of the Loan Agreement[92] Research and Development - The company has initiated a Phase 1 dose escalation and expansion study for its lead oncology program ALPN-202, targeting advanced malignancies[54] - ALPN-101, a dual ICOS and CD28 antagonist, is being developed for autoimmune and inflammatory diseases, with a Phase 2 study planned for systemic lupus erythematosus (SLE)[54] - The company plans to maximize the value of its pipeline through potential partnering activities and collaborations[54] - The company is responsible for all costs incurred under the AbbVie development plan until the license option is exercised[59] Future Outlook - The company does not expect to generate product revenue until successful completion of development and commercialization of its product candidates[57] - Future capital requirements are uncertain and will depend on various factors, including the progress of product candidates and collaboration agreements[83] - The company entered into a securities purchase agreement in July 2020, raising $60.0 million through the sale of units to institutional investors[84]